News Release

Houston Methodist ramps up plasma therapy as FDA approves clinical trial

Business Announcement

Houston Methodist

Plasma donor clinical trial

image: Eric Salazar, M.D., Ph.D. with the department of pathology and genomic medicine at the Houston Methodist Research Institute and Houston Methodist recruits recovered COVID-19 patients willing to donate plasma in hopes of saving the lives of critically ill COVID-19 patients. view more 

Credit: Houston Methodist

The FDA's announcement Friday to approve convalescent serum therapy as a large-scale clinical trial opened the door for more patients to receive the potentially life-saving gift of a donor's plasma. Houston Methodist, one of the first institutions in the country to infuse convalescent serum into a critically ill patient, immediately was able to offer the therapy to two more COVID-19 patients, bringing its total to four and leading the way to treat many more patients in the coming days.

Ten fully recovered COVID-19 patients who were tested and treated at Houston Methodist hospitals have since donated their plasma for fellow patients, and more donations are scheduled for next week. Physician scientists at Houston Methodist cautioned that the convalescent serum therapy - more than a century old and used in previous infectious outbreaks around the globe - remains experimental, and it could be some time before its effectiveness in individual patients is known.


For information on how to donate plasma, please call 346.238.4360.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.